Risk-Based Screening for Cancer in Patients With Dermatomyositis: Toward a More Individualized Approach

Affiliations

¹ School of Medicine, University of California, San Francisco.
² Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco Comprehensive Cancer Center, San Francisco.
³ Department of Dermatology, University of California, San Francisco.

Editorial

Heidi Vaughan et al. JAMA Dermatol. 2022.

. 2022 Mar 1;158(3):244-247.

doi: 10.1001/jamadermatol.2021.5841.

¹ School of Medicine, University of California, San Francisco.
² Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco Comprehensive Cancer Center, San Francisco.
³ Department of Dermatology, University of California, San Francisco.

No abstract available

Comment on

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.
Oldroyd AGS, Allard AB, Callen JP, Chinoy H, Chung L, Fiorentino D, George MD, Gordon P, Kolstad K, Kurtzman DJB, Machado PM, McHugh NJ, Postolova A, Selva-O'Callaghan A, Schmidt J, Tansley S, Vleugels RA, Werth VP, Aggarwal R. Oldroyd AGS, et al. Rheumatology (Oxford). 2021 Jun 18;60(6):2615-2628. doi: 10.1093/rheumatology/keab166. Rheumatology (Oxford). 2021. PMID: 33599244 Free PMC article.